Johnson & Johnson International (Singapore) Pte. Ltd. has on Tuesday announced a collaboration with the Singapore Economic Development Board (EDB) to unlock innovation potential in Singapore’s life sciences ecosystem.

This collaboration is the first of its kind and will leverage Johnson & Johnson Innovation – JLABS’ services and innovation resources aimed at boosting the region’s innovation output, Johnson & Johnson said in a statement.

Under this collaboration, JLABS will support early-stage companies with a base in Singapore to help accelerate their early-stage discoveries into innovative medicines, medical technologies, and healthcare solutions.

JLABS will also collaborate with local incubators and other strategic partners in the ecosystem on venture and talent development offerings to stimulate employment and commercialization opportunities for early-stage companies.

This collaboration with EDB demonstrates the ongoing commitment of Johnson & Johnson to enable and accelerate the best science and technology in the Asia Pacific region with the ambition of addressing critical unmet medical and healthcare needs.

It builds on the success of JLABS’ no-strings-approach and more than a decade of experience, as well as JLABS’ reputation as the largest global network of life science startups, investors, and corporate partners.

“At Johnson & Johnson Innovation, we source and cultivate the world’s most promising, early-stage healthcare innovation wherever it originates,

“We are thrilled to partner with EDB to advance the thriving life sciences community in Singapore and help unleash the potential of healthcare innovation in the Asia Pacific region for the rest of the world,” said William N. Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer, Johnson & Johnson.

Meanwhile, Johnson & Johnson Innovation – JLAB Global Head Melinda Richter said that the needs of the next generation of global innovators, potential partners, and early-stage companies are changing rapidly, and Johnson & Johnson is committed to pioneering new approaches to address them, like this significant collaboration with EDB.

“This type of collaboration exemplifies our pivotal role as an innovation, talent, economic and venture developer with a mission to empower our partners with the knowledge, experience, networks and practical frameworks they need to make an impact for patients,” she said.

It is also noted that Johnson & Johnson Innovation – JLABS and EDB will be co-hosting a symposium in Singapore before the end of the year, with subsequent announcements emerging from this new collaboration.

Johnson & Johnson Innovation – JLABS (JLABS) is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors.

Its goal is to catalyze and accelerate the delivery of lifesaving, life-enhancing solutions to patients around the world. JLABS is a no-strings-attached model, which means innovators are free to develop their science and technology while holding on to their intellectual property.

JLABS also produces campaigns to seek out the best science and technology called QuickFire Challenges.

Zhongchao Inc. Renews Partnership with Johnson & Johnson (China)